Latest Tax Refunds News

Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.

3P Learning confirms FY26 guidance, wins a New Zealand Ministry of Education contract, secures a $5.5 million tax refund, and signals a return to dividends with a $9.6 million payout planned.

FirstWave Cloud Technology posted a cash-flow positive Q3 FY26 with a 125% jump in customer receipts and locked in landmark contracts with Banobras and Services Australia, underpinning its AI-driven compliance strategy.

Delorean Corporation has closed its Share Purchase Plan, raising $750,000 through the issue of over 8.3 million shares at $0.09 each, supplementing earlier strategic funding from LMS Energy.

Beetaloo Energy has wrapped up its $5 million Share Purchase Plan with strong shareholder uptake, pending final approval at the upcoming AGM for new share issuance.

Delorean Corporation has banked a $5.76 million cash refund from the Australian Government’s FY2025 R&D Tax Incentive, underpinning its bioenergy infrastructure growth. Another refund linked to FY2026 expenditure is anticipated next year.

EMVision is broadening its emu™ Pivotal Trial to include acute ischaemia detection, aiming to accelerate FDA clearance and enhance the brain scanner's clinical impact. Recruitment has passed 125 patients across US and Australian sites, with full enrolment expected by early 2027.

Andromeda Metals has secured a $1.66 million cash refund from the Australian Government's R&D Tax Incentive program, reflecting $3.4 million of eligible expenditure tied to its Great White Project.

Beetaloo Energy has secured full underwriting for its $5 million Share Purchase Plan, with shareholder approval for the share issuance and any shortfall shares to be sought at the upcoming AGM on 29 May 2026.

Delorean Corporation reported solid progress in Q3 FY2026, including a positive Final Investment Decision for its NSW1 Horsley Park bioenergy facility backed by $30.5 million in grants, alongside ongoing construction at its flagship SA1 Salisbury project.

Beetaloo Energy has bolstered its financial footing with a $66.3 million equity placement and a $15.4 million R&D tax refund, underpinning key developments at the Carpentaria Gas Plant and local frac sand project.

Argenica Therapeutics is progressing its ARG-007 drug toward a targeted Phase 2b trial for acute ischaemic stroke, leveraging AI for patient selection and securing key regulatory approvals, while maintaining a solid cash position of $8 million.